Makes and sells government-approved eye-care drugs in China through a Chengdu factory whose approvals are locked to that facility.
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 0
- Scale
Makes and sells government-approved eye-care drugs in China through a Chengdu factory whose approvals are locked to that facility.
What this company is and how it runs — written from structure, not news.
Chengdu Kanghong Pharmaceutical makes ophthalmic drugs — injections and eye drops — for Chinese hospitals, and each product it sells is tied to an NMPA registration certificate that names its Chengdu sterile manufacturing facility as the approved production site. Because those certificates are non-transferable, the facility and the certificates are legally the same asset, and when a hospital procurement tender lists a formulation by its certificate number, winning that tender is a direct consequence of having won the registration years earlier. A hospital eye department that adds one of these formulations to its formulary then faces a multi-year requalification process — including bioequivalence studies and clinical validation — before any competing supplier can legally replace it, which is why existing contracts tend to stay in place. The single thing that could unravel the whole structure is a GMP compliance failure at the Chengdu site: if NMPA suspended the facility's manufacturing registration, every product whose certificate names that site would become legally unsellable at once, collapsing the hospital contract base in a single regulatory action.
How does this company make money?
The company earns money each time a finished ophthalmic drug is sold. Most sales flow through Chinese hospital procurement tenders, where hospital eye departments order approved formulations by certificate number. The company also sells directly to ophthalmic specialty clinics. Every unit sold is a physical drug — an injection or a drop — made at the Chengdu facility.
What makes this company hard to replace?
NMPA registration certificates cannot be transferred from one manufacturer to another, so a hospital cannot simply swap in a competitor's version of the same drug. Hospital procurement contracts require a full multi-year requalification cycle before a new supplier can legally replace an existing one. That requalification includes bioequivalence studies and clinical validation — a long, expensive process that gives hospital eye departments a strong practical reason to stay with the registered product already in their formulary.
What limits this company?
Getting a new eye-care drug approved by China's NMPA takes between three and seven years, and no amount of money can make that go faster. That timeline is the hard ceiling on how quickly the company can add new products and grow revenue. The number of registrations moving through the pipeline at any one moment sets the maximum speed of growth.
What does this company depend on?
The company cannot operate without five things: NMPA drug registration certificates for each marketed ophthalmic product; active pharmaceutical ingredients sourced from qualified API suppliers; sterile manufacturing equipment validated specifically for ophthalmic formulations; aseptic filling technology for injectable eye products; and continued access to the Chinese hospital procurement system.
Who depends on this company?
Chinese ophthalmic hospitals would lose access to specific registered eye-disease treatments and would need to find alternative sources, which could take years. Ophthalmic specialists would face treatment gaps for patients who depend on these particular formulated therapies. Hospital pharmacy procurement teams would have to identify and qualify substitute suppliers for contracted specialty eye drugs — a lengthy and uncertain process.
How does this company scale?
Adding more production capacity is relatively straightforward: the company can build additional sterile filling lines and scale up batch sizes for already-approved formulations. What does not scale with money is the registration pipeline — each new ophthalmic indication must go through years of clinical work and NMPA review regardless of how much capital is available. As the company grows, the production side can expand, but the pace of new products remains gated by regulatory timelines.
What external forces can significantly affect this company?
Chinese healthcare reform policies can change how hospitals price and select specialty drugs in procurement, directly affecting which products get included and at what price. Renminbi currency swings affect what the company pays for imported active pharmaceutical ingredients. On the positive side, China's aging population is increasing demand for treatments targeting age-related eye conditions, which could expand the market the company sells into.
Where is this company structurally vulnerable?
If the Chengdu facility failed a GMP inspection and NMPA suspended the manufacturing-site registration behind multiple certificates at once, every product tied to those certificates would become illegal to sell immediately. All hospital contracts that reference those certificate numbers would stop being executable in the same moment — the entire revenue base would collapse in a single regulatory action.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: the fast moving average is above the slow moving average, trend strength is elevated, and volume is above baseline.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
Screen for dividend patterns
Find other stocks with similar dividend characteristics in the screener.
The reported statements, read against the company's own industry.
11 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Two cash observations have aligned: the cash ratio (cash divided by current liabilities) is in the upper industry-benchmarked range, and cash represents a meaningful share of total assets.
Three observations have aligned: most-recent-quarter total cash equals or exceeds most-recent-quarter total debt, EBITDA-to-total-liabilities is in the upper portion of its mapped range, and FCF-to-total-liabilities is in the upper portion of its mapped range.
Three liquidity ratios co-occur in their elevated ranges: current ratio (industry-benchmarked), quick ratio, and cash ratio. The simultaneous firing means coverage is elevated through progressively more liquid asset layers, not concentrated in inventory or receivables.
Three balance-sheet observations co-occur: industry-benchmarked current ratio elevated, industry-benchmarked equity ratio elevated, and total cash at MRQ at least equal to total debt. The configuration describes equity-heavy capital structure with cash covering total debt.
How does this company use capital?
Three observations co-occur: the weighted composite of net cash relative to market cap, OCF/revenue, operating margin, and ROE is in its elevated range; revenue increased every year for three years; net income was positive every year for three years. The configuration describes a present-state combination of capital structure, cash generation, profitability, and top-line growth.
Three margin observations have aligned: industry-benchmarked gross profit margin is in the upper peer range, operating income margin is in the upper portion of its mapped range, and industry-benchmarked TTM operating cash flow margin is in the upper peer range.
Three margin observations have aligned: industry-benchmarked gross profit margin is in the upper peer range, operating income margin is in the upper portion of its mapped range, and industry-benchmarked net profit margin is in the upper peer range.
Four observations co-occur: free cash flow positive each of the last three fiscal years, revenue increased each of the last three fiscal years, trailing-statistics OCF margin elevated, and book value increased each of the last four fiscal years. The configuration describes multi-year fundamental persistence across cash flow, top line, margin, and equity accumulation.
Three observations co-occur: free cash flow has been positive each of the last three fiscal years, ADX directional-movement asymmetry is elevated, and the 50-week SMA sits above the 200-week SMA. The set describes past free-cash-flow generation alongside lopsided directional movement and a present-state price/SMA geometry.
Is this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
How is this stock valued?
Retained earnings are a large share of total assets; net income was positive in each of the last 5 fiscal years; shareholders' equity is a large share of total assets.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph